Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pilocarpine + timolol
- Development stage
- Unknown
- Lead developer
- Bruschettini
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Equiton is a fixed-dose combination ophthalmic solution containing the miotic cholinergic agonist pilocarpine hydrochloride and the non-selective beta-adrenergic receptor antagonist timolol maleate. Developed by Bruschettini, it is approved for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension, open-angle glaucoma, or narrow-angle glaucoma. Pilocarpine acts as an agonist at muscarinic acetylcholine receptors (primarily M3), causing contraction of the iris sphincter and ciliary muscles to facilitate the drainage of aqueous humor through the trabecular meshwork. Timolol blocks beta-1 and beta-2 adrenergic receptors in the ciliary body, thereby reducing the production of aqueous humor. Together, these two active ingredients provide a synergistic reduction in intraocular pressure with a convenient twice-daily dosing regimen.
- Brand names
- Equiton
- Other names
- pilocarpine + timololpilocarpine hydrochloride + timolol maleatepilocarpine/timololtimolol + pilocarpinetimolol/pilocarpine
02
Targets
ADRB1 (β1)ADRB2 (β2)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)
Beyond the preview
Go deeper on pilocarpine + timolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pilocarpine + timolol.